Journals / Klimik Dergisi / 2016 / Cilt: 29 - Sayı: 3

Antimicrobial Resistance of Enterococci Isolated From Urine Cultures

İdrar Kültürlerinden İzole Edilen Enterokok Suşlarında Antimikrobiyal Direnç

Pages
112–116
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results of antimicrobial susceptibility testing are important for choosing appropriate treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the susceptibility of enterococcal strains isolated from both nosocomial and community-acquired urinary tract infections between January 2011 and December 2014, and also to compare the resistance rates between January 2011-December 2012 and January 2013-December 2014 periods.Methods: The identification of the strains and antimicrobial susceptibility rates were determined by BD Phoenix (Becton, Dickinson and Company., Sparks, Maryland, USA) and VITEK® 2 (bioMérieux, Marcy l'Etoile, Fransa) automatized systems.
📊
Key Findings & Data:Results: All isolates (n=156) were found to be susceptible to vancomycin, teicoplanin, linezolid and tigecycline.
💡
Conclusion & Impact:Results of antimicrobial susceptibility testing are important for choosing appropriate treatment.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the susceptibility of enterococcal strains isolated from both nosocomial and community-acquired urinary tract infections between January 2011 and December 2014, and also to compare the resistance rates between January 2011-December 2012 and January 2013-December 2014 periods.Methods: The identification of the strains and antimicrobial susceptibility rates were determined by BD Phoenix (Becton, Dickinson and Company., Sparks, Maryland, USA) and VITEK® 2 (bioMérieux, Marcy l'Etoile, Fransa) automatized systems. Results: All isolates (n=156) were found to be susceptible to vancomycin, teicoplanin, linezolid and tigecycline. Penicillin, ampicillin, ciprofloxacin, nitrofurantoin, tetracycline, fosfomycin, gentamicin (high-level) and streptomycin (high-level) resistance rates were 60.9, 8.7, 15.2, 4.3, 73.9, 6.5, 15.2 and 26.1% in nosocomial Enterococcus faecalis isolates (n=46), respectively; and 100, 100, 28.6, 65.7, 42.9, 8.6, 17.1 and 31.4% in nosocomial E. faecium isolates (n=35), respectively. Comparison of data between January 2011-December 2012 and January 2013-December 2014 periods revealed significant increases in resistance rates to penicillin, ciprofloxacin, and streptomycin (high-level) in nosocomial E. faecalis isolates and to ciprofloxacin and streptomycin (high-level) in nosocomial E. faecium isolates. In community-acquired E. faecalis isolates, the resistance rates for penicillin and ciprofloxacin were found to be increased in the second period of the study.Conclusions: High-level aminoglycoside and quinolone resistance rates in enterococci were significantly increased in our hospital. Results of antimicrobial susceptibility testing are important for choosing appropriate treatment.

Özet

Amaç: Bu çalışmada üriner sistem infeksiyonu etkeni olarak Ocak 2011-Aralık 2014 arasında izole edilen hastane kökenli ve toplum kökenli enterokokların antimikrobiyal direnç durumlarının belirlenmesi ve Ocak 2011-Aralık 2012 ve Ocak 2013-Aralık 2014 dönemleri arasındaki direnç oranlarının karşılaştırılması amaçlanmıştır.Yöntemler: İzolatların tanımlanması ve antimikrobiyal duyarlılıkları BD Phoenix (Becton, Dickinson Company, Sparks, Maryland, ABD) ve VITEK® 2 (bioMérieux, Marcy l'Etoile, Fransa) otomatize sistemleriyle gerçekleştirilmiştir. Bulgular: Tüm enterokok izolatları (n=156) vankomisin, teikoplanin, linezolid ve tigesikline duyarlı bulunmuştur. Hastane kökenli Enterococcus faecalis izolatlarının (n=46) %60.9'u penisiline, %8.7'si ampisiline, %15.2'si siprofloksasine, %4.3'ü nitrofurantoine, %73.9'u tetrasikline, %6.5'i fosfomisine, %15.2'si gentamisine (yüksek düzey) ve %26.1'i streptomisine (yüksek düzey) dirençliydi. Hastane kökenli E. faecium izolatlarının (n=35) %100'ü penisiline ve ampisiline, %28.6'sı siprofloksasine, %65.7'si nitrofurantoine, %42.9'u tetrasikline, %8.6'sı fosfomisine, %17.1'i gentamisine (yüksek düzey) ve %31.4'ü streptomisine (yüksek düzey) dirençli olarak saptanmıştır. Ocak 2013-Aralık 2014 döneminde, Ocak 2011-Aralık 2012 dönemine göre hastane kökenli E. faecalis izolatlarında penisilin, siprofloksasin ve streptomisine (yüksek düzey); hastane kökenli E. faecium izolatlarında siprofloksasin ve streptomisine (yüksek düzey), toplum kökenli E. faecalis izolatlarında penisilin ve siprofloksasine direnç artmıştır.Sonuçlar: Hastanemizde idrar kültürlerinden izole edilen enterokoklarda özellikle kinolon ve yüksek düzey aminoglikozid direnci belirgin olarak artmıştır. Uygun tedavinin seçilmesinde antimikrobiyal duyarlılık testlerinin sonuçları önemlidir.

🔖

Cite This Article

BULUT, Y., YENİŞEHİRLİ, G., YENİŞEHİRLİ, A., ÖZVEREN, G. (2022). Antimicrobial Resistance of Enterococci Isolated From Urine Cultures. Klimik Dergisi, Cilt: 29 - Sayı: 3, 112–116. https://ajindex.com/articles/573572

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Poh CH, Oh HM. Tan AL. Epidemiology and clinical outcome of enterococcal bacteraemia in an acute care hospital. J Infect. 2006; 52(5): 383-6. [CrossRef] Teixeira LM, Carvalho MGS, Shewmaker PL, Facklam RR. Ente- rococcus. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology. 10th ed. Was- hington, DC: ASM Press, 2011: 350-64. [CrossRef] Cetinkaya Y, Falk P, Mayhall CG. Vancomycin resistant enterococ- ci. Clin Microbiol Rev. 2000; 13(4): 686-702. [CrossRef] Clinical and Laboratory Standards Institute. Performance Stan- dards for Antimicrobial Susceptibility Testing. Twentieth Infor- mational Supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010. Breakpoint Tables for Interpretation of MICs and Zone Diame- ters. Version 4.0, Valid until Dec 31, 2014 [İnternet]. Basel, Swit- zerland: European Committee on Antimicrobial Susceptibility Testing (EUCAST) [erişim 1 Eylül 2015]. http://www.eucast.org/ fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Bre- akpoint_table_v_4.0.xls. Murray BE. Vancomycin-resistant enterococci. Am J Med. 1997; 102(3): 284-93. [CrossRef] Yavuz MT, Şahin İ, Öztürk E, Behçet M, Kaya D. Hastane kökenli üriner sistem infeksiyonlarından izole edilen Enterococcus tür- lerinin insidansı ve antibiyotik direnç profilleri. Türk Mikrobiyol Cemiy Derg. 2006; 36(4): 195-9.
  2. Gazi H, Kurutepe S, Sürücüoğlu S, Ecemiş T, Özbakkaloğlu B. Hastane kökenli Enterococcus faecalis ve Enterococcus faeci- um suşlarında antimikrobiyal direnç. Ankem Derg. 2004; 18(1): 49-52.
  3. Bilici D, Aktaş O, Özbek A, Bilici S. Klinik örneklerden izole edi- len enterokokların tedavide kullanılan antibiyotiklere karşı in vitro dirençlerinin araştırılması. Klimik Derg. 2013; 26(3): 102-7. [CrossRef] Kalaycı Ö, Yurtsever SG, Güngör S, Uzun B, Kurultay N. İdrar ör- neklerinden izole edilen enterokokların in vitro antibiyotik direnç oranlarının değerlendirilmesi. Klimik Derg. 2011; 24(2): 105-7. [CrossRef] Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resis- tant enterococci. Lancet. 1988; 1(8575-6): 57-8.
  4. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated re- sistance to vancomycin and teicoplanin in Enterococcus faeci- um. N Engl J Med. 1988; 319(3): 157-61. [CrossRef] O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infec- tions: epidemiology, clinical manifestations, and optimal mana- gement. Infect Drug Resist. 2015; 8: 217-30.
  5. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathog